Full Year 2025 Roche Holding AG Earnings Call Transcript
Key Points
- Roche Holding AG (RHHBF) reported strong pipeline progress with 10 NMEs moving into Phase III, a record for the company.
- The company has seen positive Phase III readouts for several key drugs, including giredestrant and fenebrutinib, which are expected to become new standards of care in their respective fields.
- Roche Holding AG (RHHBF) has secured a contract with the US government, providing exemptions from tariffs and demo projects, in exchange for Medicaid rebates and investments in the US.
- The company has a strong on-market portfolio with 16 blockbusters across five therapeutic areas, contributing to sustained growth momentum.
- Roche Holding AG (RHHBF) expects mid-single-digit sales growth and high single-digit core EPS growth for 2026, with plans to further increase dividends in Swiss francs.
- Roche Holding AG (RHHBF) faced headwinds in China due to healthcare pricing reforms, impacting sales growth in the Diagnostics division.
- The company's cash flow decreased from CHF20.2 billion to CHF16.2 billion, partly due to increased accounts receivables and inventory levels.
- The Diagnostics division experienced a decline in core operating profit margin due to increased costs related to new technology production and healthcare reforms in China.
- Roche Holding AG (RHHBF) anticipates a continued impact from currency fluctuations, with a potential negative effect on sales and core operating profit in 2026.
- The company faces challenges from biosimilar competition, particularly in the US and Europe, which could impact sales of key products like Xolair and Perjeta.
(audio in progress) two guidances every time in '24 and '25.
Now what's super exciting is the growth outlook. And the growth outlook has fundamentally changed based on some of the Phase III readouts that we have seen in Q4. Giredestrant, our [1/3] has had 2 positive readouts, one with evERA. And the second 1 with lidERA. lidERA reading out early, we expected the readout only next year. But based on the very significant results, it's read out early already this year. We're now waiting for the persevERA data, but we clearly see that we have a very active and very good molecule in hand. Not only is it going to rebase the standard of care and is going to become the new backbone in this field. But it's so safe that and tolerable that we do believe that this will become the standard of care.
Fenebrutinib in MS, we had 2 positive studies here in RMS and in PPMS. I know Teresa will go into that. We're still waiting for the second FENhance 1 study in RMS in order to be able to file this.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
